The intrinsic subtypes of breast cancer have been elucidated with advances in cancer genomics, which lead to the generalization of therapies by targeting human epidermal growth factor receptor 2 (HER2) for HER2-positive patients and endocrine therapy for hormone receptor-positive patients (2, 3). Here, ERBB2 is linked to cancer.